{"id":2824,"date":"2021-11-30T10:03:49","date_gmt":"2021-11-30T09:03:49","guid":{"rendered":"https:\/\/wp.idlbiotech.com\/?page_id=2824"},"modified":"2026-02-24T14:38:43","modified_gmt":"2026-02-24T13:38:43","slug":"board-of-directors","status":"publish","type":"page","link":"https:\/\/idldiagnostics.com\/se\/investors\/corporate-governance\/board-of-directors\/","title":{"rendered":"Styrelse och verkst\u00e4llande direkt\u00f6rer"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”88f366a5-bf49-48d9-a338-ab22706b73e7″ global_colors_info=”{}”][et_pb_row _builder_version=”4.18.0″ _module_preset=”default” custom_padding=”0px||0px|||” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”||||false|false” custom_padding_tablet=”10px||||false|false” custom_padding_phone=”0px||||false|false” custom_padding_last_edited=”on|phone” global_colors_info=”{}”][dipi_breadcrumbs _builder_version=”4.27.4″ _module_preset=”default” max_width=”800px” global_module=”5132″ global_colors_info=”{}”][\/dipi_breadcrumbs][et_pb_divider color=”#EEEEEE” _builder_version=”4.16″ _module_preset=”default” max_width=”800px” min_height=”1px” height=”20px” custom_margin=”||3px|||” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.18.0″ _module_preset=”8738c908-7375-4c6c-99a7-9f91f8a3c099″ header_font_size=”56px” max_width=”800px” custom_margin=”||17px|||” global_colors_info=”{}”]<\/p>\n

Board<\/h6>\n

Board of directors<\/h1>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”board” _builder_version=”4.16″ _module_preset=”e9afc0e7-c9bf-4a12-be49-63ddba231101″ border_width_bottom=”0px” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Board of directors<\/h3>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_2,1_2″ make_equal=”on” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” background_color=”#F8F8F8″ border_radii=”on|20px|20px|20px|20px” global_colors_info=”{}”][et_pb_testimonial portrait_url=”https:\/\/idldiagnostics.com\/wp-content\/uploads\/2022\/05\/max-pihlqvist.jpg” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Chairman, M.B.A.<\/span><\/h6>\n

Max Pihlqvist<\/h3>\n

Max Pihlqvist has a master\u2019s degree in business administration from Lund University and significant experience in the laboratory and diagnostics industry. Max Pihlqvist has previous experience from IDL Biotech as a board member during the years 2017-2019.<\/p>\n

Today, Max works as CEO of the Svenska Labex AB Group with subsidiaries in Norway and Denmark and is Chairman of the Board of Labex Holding AB, Norsk Labex AS, Labex APS and Labex Reagens AB.<\/p>\n

Board member since 2022<\/p>\n

Holdings in IDL Diagnostics: 44,411,786 privately and <\/strong><\/span><\/p>\n

Dependent in relation to one of\u00a0the company\u2019s major shareholders,\u00a0independent in relation to\u00a0the company and its management.<\/span>\u00a0<\/span><\/p>\n

[\/et_pb_testimonial][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” background_color=”#F8F8F8″ border_radii=”on|20px|20px|20px|20px” global_colors_info=”{}”][et_pb_testimonial portrait_url=”https:\/\/idldiagnostics.com\/wp-content\/uploads\/2021\/12\/Eva-Nordstrom.png” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

Ph.D.<\/h6>\n

Eva Nordstr\u00f6m<\/h3>\n

Eva has a Ph.D. in immunology under Prof. Erna M\u00f6ller at Stockholm University and is currently working as a Senior Researcher at BioArctic AB. She has wide scientific experience from assay development, hybridoma generation and immunoassays.<\/p>\n

Board member since 2020<\/p>\n

Holdings in IDL Diagnostics: 120,000 shares.<\/strong><\/p>\n

Independent in relation to the company and its management and in relation to major shareholders.<\/p>\n

<\/strong><\/p>\n

[\/et_pb_testimonial][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_2,1_2″ make_equal=”on” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” background_color=”#F8F8F8″ border_radii=”on|20px|20px|20px|20px” global_colors_info=”{}”][et_pb_testimonial portrait_url=”https:\/\/idldiagnostics.com\/wp-content\/uploads\/2022\/10\/Agneta-Tufvesson-Alm.jpeg” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

B.S.Chem.<\/h6>\n

Agneta Tufvesson Alm<\/h3>\n

Agneta Tufvesson Alm has more than 30 years of experience in international sales and marketing as well as experience in direct sales in the Nordic countries and the United Kingdom, region and key account management in Europe, Africa, and the Middle East. Agneta has worked with building distribution networks, contract negotiations, and management of sales and customer service teams. She currently works at Kemira Kemi AB and has previously held roles at HemoCue AB, Thermo Quest, and Kabi Pharmacia. Agneta has a bachelor\u2019s degree in chemistry from Lund University.<\/p>\n

Board member since 2022<\/p>\n

Holdings in IDL Diagnostics: 20,000 shares<\/strong><\/p>\n

Independent in relation to the company and its management and in relation to major shareholders.<\/p>\n